Cancer Policy FDA launches Rare Disease Framework Initiative for drug development October 16, 2026Vol.52 No.38
Cancer Policy FDA seeks nominations for the Tobacco Products Scientific Advisory Committee, announces new members October 16, 2026Vol.52 No.38
Drugs & Targets FDA approves atezolizumab + chemotherapy for stage 3 colon cancer October 16, 2026Vol.52 No.38
Drugs & Targets FDA expands Anktiva approval for BCG-unresponsive non-muscle-invasive bladder cancer to cover both papillary and CIS disease October 16, 2026Vol.52 No.38
Podcast As FDA sidesteps the question of Galleri’s clinical benefit, NCI’s Letai has “some concerns” October 14, 2026
Drugs & Targets FDA approves tucatinib + trastuzumab + pertuzumab for maintenance treatment of HER2+ breast cancer October 09, 2026Vol.52 No.37
Regulatory News Two years after FDA’s breast density notification rule, there is still no standard for follow-upSo far, 38 million patients have received a dense breast notification. Now what? October 02, 2026Vol.52 No.36By Claire Marie Porter
Regulatory News MD Anderson study suggests psilocybin may prevent chemo-induced neuropathy“Because it works in one neural system, you begin to wonder: Well, what about another?” October 02, 2026Vol.52 No.36By Sara Willa Ernst
Drugs & Targets FDA approves Degevma, a biosimilar for cancer-related bone complications October 02, 2026Vol.52 No.36
Drugs & Targets FDA approves Ponlimsi, a biosimilar for preventing fractures in prostate and breast cancer patients October 02, 2026Vol.52 No.36
